期刊
EXPERIMENTAL DERMATOLOGY
卷 28, 期 2, 页码 198-201出版社
WILEY
DOI: 10.1111/exd.13850
关键词
2-DG; glucose; glucose metabolism; imiquimod; psoriasis; therapy
类别
资金
- National Natural Science Foundations of China [81430075]
- Key Technology Research and Development Program of Hunan Province [2014FJ6010]
- Hunan population and Family Planning Commission [B2016066]
Psoriasis is a common chronic disease with accelerated epidermal cell growth. Solute carrier family 2 member 1 (SLC2A1), also named GLUT1, transports glucose and its analogues into cells. With elevated membrane-bound GLUT1, psoriatic keratinocytes uptake more glucose with increased glucose metabolism. Competition between glucose and its analogues can serve as a strategy to inhibit glycolysis as well as proliferation. In this study, we investigated the expression patterns of GLUT1 in keratinocytes in the human psoriasis vulgaris and imiquimod-induced psoriasis model, and determined that the glucose metabolism inhibitor 2-deoxy-D-glucose (2-DG) can relieve the psoriatic lesions. We found membrane-enriched GLUT1 in psoriasis keratinocytes, which suggested some potential for glucose metabolic target therapy based on the glycolytic microenvironment. Furthermore, 2-DG was able to relieve the psoriatic lesions in an in vivo animal model which provides a new possible therapeutic strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据